Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTT-2: baricitinib plus remdesivir versus remdesivir for hospitalized adults with COVID-19
jRCT2031200035Completed
- Sponsor
- Ministry of Health, Labour and Welfare
- Start
- Jun 2020
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
01
Overview
Randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Baricitinib + remdesivir with Placebo + remdesivir (2 arms). Primary endpoints: Time to recovery and Clinical status at Day 15. Started Jun 2020; status: completed.
02
Drugs
baricitinibremdesivir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2031200035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200035.